ATE547107T1 - Verwendung von selenhefe in der behandlung von alzheimers krankheit - Google Patents

Verwendung von selenhefe in der behandlung von alzheimers krankheit

Info

Publication number
ATE547107T1
ATE547107T1 AT05024235T AT05024235T ATE547107T1 AT E547107 T1 ATE547107 T1 AT E547107T1 AT 05024235 T AT05024235 T AT 05024235T AT 05024235 T AT05024235 T AT 05024235T AT E547107 T1 ATE547107 T1 AT E547107T1
Authority
AT
Austria
Prior art keywords
disease
selenium
alzheimer
treatment
present
Prior art date
Application number
AT05024235T
Other languages
English (en)
Inventor
Lyons Thomas Pearse
Ronan Power
Original Assignee
Alltech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alltech Inc filed Critical Alltech Inc
Application granted granted Critical
Publication of ATE547107T1 publication Critical patent/ATE547107T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT05024235T 2005-10-14 2005-11-07 Verwendung von selenhefe in der behandlung von alzheimers krankheit ATE547107T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US72692205P 2005-10-14 2005-10-14
US72701805P 2005-10-14 2005-10-14
US72701505P 2005-10-14 2005-10-14
US72695105P 2005-10-14 2005-10-14

Publications (1)

Publication Number Publication Date
ATE547107T1 true ATE547107T1 (de) 2012-03-15

Family

ID=35734026

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05024235T ATE547107T1 (de) 2005-10-14 2005-11-07 Verwendung von selenhefe in der behandlung von alzheimers krankheit

Country Status (14)

Country Link
EP (5) EP1779856A1 (de)
JP (1) JP4753683B2 (de)
CN (2) CN101073584B (de)
AT (1) ATE547107T1 (de)
AU (1) AU2005227420B2 (de)
CY (1) CY1112790T1 (de)
DK (2) DK1779858T3 (de)
ES (2) ES2382334T3 (de)
HR (1) HRP20120337T1 (de)
PL (2) PL1779858T3 (de)
PT (2) PT1774972E (de)
RS (2) RS52257B (de)
SI (1) SI1774972T1 (de)
TW (1) TWI319708B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2394348T3 (es) * 2006-03-29 2013-01-30 Velacor Therapeutics Pty Ltd Tratamiento de enfermedades neurodegenerativas con selenato
EP2012806A4 (de) * 2006-04-24 2010-07-28 Alltech Inc Verfahren und zusammensetzungen zur veränderung von zellfunktionen
LT3028716T (lt) 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
US7696251B2 (en) 2007-02-12 2010-04-13 Incorporated National University Iwate University Method for inhibiting neuronal cell death induced by oxidative glutamate toxicity
WO2008119109A1 (en) * 2007-03-29 2008-10-09 Velacor Therapeutics Pty Ltd Treatment of neurological disorders
US8987245B2 (en) 2008-04-02 2015-03-24 Jonathan R. Brestoff Parker Composition and method for affecting obesity and related conditions
US8598150B1 (en) 2008-04-02 2013-12-03 Jonathan R. Brestoff Composition and method for affecting obesity and related conditions
US9493834B2 (en) 2009-07-29 2016-11-15 Pharnext Method for detecting a panel of biomarkers
WO2011023769A1 (en) * 2009-08-26 2011-03-03 Mb Milmed Ab Composition for treatment of neurodegenerative diseases or disorders, method and use comprising electromagnetically irradiated yeast
US8263752B2 (en) * 2010-03-18 2012-09-11 Alltech, Inc. Methods for separating soluble selenoglycoproteins
WO2012095548A2 (es) * 2011-01-13 2012-07-19 Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) Compuestos para el tratamiento de enfermedades neurodegenerativas
US9833486B2 (en) * 2013-03-15 2017-12-05 Alltech, Inc. Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
WO2015006507A1 (en) 2013-07-09 2015-01-15 Annexon, Inc. Methods of treatment for alzheimer's disease and huntington's disease
CN103848898B (zh) * 2014-02-17 2016-01-27 南昌大学 双酚A的抗原模拟表位Ph3及其应用
RU2665135C2 (ru) * 2014-03-14 2018-08-28 Олтек, Инк. Композиции селеноорганических соединений и способы их применения
HUE070383T2 (hu) 2014-11-05 2025-06-28 Annexon Inc Humanizált C1Q anti-komplement faktor antitestek és alkalmazásaik
CN104825498A (zh) * 2015-03-30 2015-08-12 安徽省华信生物药业股份有限公司 硒酵母在阿尔茨海默病防治中的应用
WO2017048252A1 (en) * 2015-09-15 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
WO2017091719A1 (en) 2015-11-24 2017-06-01 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof
US10702571B2 (en) 2015-12-03 2020-07-07 The University Of North Carolina At Pembroke Materials for cathepsin B enhancement and methods of use
EP4379376A3 (de) * 2017-09-07 2024-07-17 The Children's Hospital Of Philadelphia Zusammensetzungen und verfahren zur behandlung von hereditärer cystatin-c-amyloidangiopathie (hccaa) und anderen neurodegenerativen erkrankungen im zusammenhang mit aberranter amyloidablagerungen
CN111458517B (zh) * 2020-03-13 2022-08-16 深圳大学 Selenof作为阿尔茨海默病药物靶点的应用
WO2023114763A1 (en) 2021-12-13 2023-06-22 Annexon, Inc. Anti-complement factor c1q antibodies with single binding arms and uses thereof
PL440896A1 (pl) 2022-04-11 2023-10-16 Uniwersytet Gdański Genisteina do zastosowania w zapobieganiu utraty pamięci i zdolności poznawczych ludzi zdrowych w wyniku stopniowych występujących fizjologicznie u osób zdrowych procesów starzenia się mózgu z wiekiem jako czynnik zapobiegający i zmniejszający odkładanie się szkodliwych nierozpuszczalnych agregatów i złogów białek w mózgu, zwłaszcza beta-amyloidu
CN115910112A (zh) * 2022-12-06 2023-04-04 重庆大学 一种帕金森病受试者包络化语音样本段分级融合方法
WO2025151942A1 (pt) * 2024-01-18 2025-07-24 Moro Peres Nemecio Suplemento alimentar particularmente indicado para prevenção do declínio cognitivo, cápsula compreendendo o dito suplemento e uso do mesmo
CN118308420B (zh) * 2024-04-19 2025-06-03 东北农业大学 一种大豆基因Glyma.18G041900的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT397200B (de) * 1988-06-03 1994-02-25 Birkmayer Joerg Ddr Verwendung von selenmethionin zur herstellung eines arzneimittels
GB9001121D0 (en) * 1990-01-18 1990-03-21 Efamol Holdings Efa compositions and therapy
US5221545A (en) 1992-03-09 1993-06-22 Abbott Laboratories Method of providing selenium in a nutritional product
DE4413839C1 (de) * 1994-04-21 1995-10-19 Fritz Koch Pharma Gmbh Dr Med Kombinationspräparat
JPH09323939A (ja) * 1996-06-03 1997-12-16 R T Ee Assoc Kk 抗痴呆剤
AU720643B2 (en) * 1996-08-13 2000-06-08 P.N. Gerolymatos S.A. Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of Alzheimer's disease
US6197295B1 (en) 1996-09-25 2001-03-06 Viva America Marketing Corporation Dietary supplementation with, and methods for administration of yeast-derived selenium product
EP0983062A4 (de) * 1997-05-21 2002-10-23 Sloan Kettering Inst Cancer Verfahren zur erhöhung der konzentration von ascobinsäure im hirngewebe von personen
JPH11199599A (ja) * 1997-12-09 1999-07-27 Adriel Dell Calpio Carlos 補体活性阻害性ペプチドおよび抗補体剤
FR2774596B1 (fr) * 1998-02-11 2000-03-17 Rhone Poulenc Rorer Sa Utilisation de composes selenies dans la prevention et le traitement de la maladie d'alzheimer
AU6384099A (en) * 1998-08-31 2000-03-21 Proteotech, Inc. Blended compositions for treatment of alzheimer's disease and other amyloidoses
ATE362486T1 (de) * 1999-04-06 2007-06-15 Univ California Menschliche, für neurogenin 3 kodierende nukleotidsequenzen
CA2325041A1 (en) * 2000-11-17 2002-05-17 Eddie Lo Ultra-vit. plus
DE10158180A1 (de) * 2001-11-28 2003-09-11 Biovision Ag Verfahren zum Nachweis von Morbus Alzheimer und zur Unterscheidung von Morbus Alzheimer gegenüber anderen demenziellen Erkrankungen, zugehörige Peptide und deren Verwendung
CA2470539C (en) * 2001-12-07 2011-10-04 Geron Corporation Islet cells from human embryonic stem cells
GB0202900D0 (en) * 2002-02-07 2002-03-27 Laxdale Ltd Novel formulations of drugs
DK174835B1 (da) * 2002-03-15 2003-12-15 Pharma Nord Aps Selengærprodukt, fremgangsmåde til fremstilling af et selengærprodukt samt anvendelse af produktet til fremstilling af en fødevare, et kosttilskud, eller et lægemiddel
CN1403017A (zh) * 2002-10-24 2003-03-19 田轩 富硒魔芋绿茶保健食品
US6911550B2 (en) 2003-02-21 2005-06-28 Zinpro Corporation Derivatives of seleno-amino acids with improved bioavailability and method for their preparation
CN1440665A (zh) * 2003-04-01 2003-09-10 宁夏长宁实业（集团）有限公司乳业分公司 富含硒及超氧化物歧化酶乳制品及其生产方法
JP2004344079A (ja) * 2003-05-23 2004-12-09 Sceti Co Ltd チャーガを含有する健康補助食品
KR20060040676A (ko) * 2003-07-11 2006-05-10 미리어드 제네틱스, 인크. 알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형
US20050069594A1 (en) 2003-08-11 2005-03-31 Jan Lubinski Pharmaceutical compositions and methods for the prevention of breast and ovarian cancer
UY28650A1 (es) * 2003-12-05 2005-02-28 Forest Laboratories Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta
CN1569123A (zh) * 2004-04-30 2005-01-26 成进学 用蛇、蜂、宏、微量元素强化中药方剂的内服功能性药剂及其生产工艺

Also Published As

Publication number Publication date
CY1112790T1 (el) 2016-02-10
EP1779856A1 (de) 2007-05-02
EP2087895A1 (de) 2009-08-12
CN101073584B (zh) 2012-10-10
JP2007106732A (ja) 2007-04-26
AU2005227420B2 (en) 2013-05-09
DK1774972T3 (da) 2012-05-14
HRP20120337T1 (hr) 2012-05-31
PT1779858E (pt) 2013-04-08
TW200714277A (en) 2007-04-16
RS52666B (sr) 2013-06-28
EP1774972B1 (de) 2012-02-29
ES2382334T3 (es) 2012-06-07
RS52257B (sr) 2012-10-31
CN102764279B (zh) 2015-04-01
EP1779857A1 (de) 2007-05-02
AU2005227420A1 (en) 2007-05-03
DK1779858T3 (da) 2013-02-04
CN101073584A (zh) 2007-11-21
EP1779858B1 (de) 2013-01-09
ES2402365T3 (es) 2013-05-03
EP1779858A1 (de) 2007-05-02
PL1774972T3 (pl) 2012-08-31
PL1779858T3 (pl) 2013-06-28
SI1774972T1 (sl) 2012-06-29
TWI319708B (en) 2010-01-21
EP1774972A1 (de) 2007-04-18
CN102764279A (zh) 2012-11-07
PT1774972E (pt) 2012-05-21
JP4753683B2 (ja) 2011-08-24

Similar Documents

Publication Publication Date Title
ATE547107T1 (de) Verwendung von selenhefe in der behandlung von alzheimers krankheit
DE602004009295D1 (de) 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie
EA200870019A1 (ru) Лактамовые соединения и способы их применения
WO2006121610A3 (en) Personal care compositions and methods for their use
ATE503482T1 (de) Verwendung von pirlindol bei der behandlung von erkrankungen; die durch proliferation von t- lymphozyten und/oder hyperproliferation von keratinozyten gekennzeichnet sind; insbesondere atopische dermatitis und psoriasis
DE602005011279D1 (de) Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
DK1567488T3 (da) Hydroxyethylaminderivater til behandling af Alzheimers sygdom
NO20060230L (no) Nye aminobenzofenonforbindelser
SE0201980D0 (sv) Novel compounds
MA30983B1 (fr) Composes chimiques et leurs utilisations
NO20071378L (no) Tiazolo-naftylsyrer.
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
EA200601223A1 (ru) Производные сульфонамида для лечения заболеваний
NO20055130D0 (no) Aminocykloheksyleter-forbindelser og deres anvendelse
ATE333451T1 (de) Verwendung von nitrilenverbindungen als arztneimittel
ATE542536T1 (de) 3-ä4-(dibenzoäb,füä1,4üoxazepin-11-yl)-piperazi - 1-ylü-2,2-dimethyl propansäure zur verwendung in der behandlung von schlafstörungen
NO20055741D0 (no) Nye kjemiske forbindelser
DE502005009908D1 (de) Verwendung von fluoreszierenden perlylenverbindungen zur behandlung menschlicher haare
DE60313803D1 (de) Cathepsincysteinproteaseinhibitoren und deren verwendung zur behandlung von entzündungen und immunerkrankungen
ATE489948T1 (de) Behandlung von autoimmunkrankheiten
ATE494008T1 (de) Verwendung eines p38-kinasehemmers zur behandlung von psychiatrischen erkrankungen
CY1111678T1 (el) Σταθεροποιημενες και διατηρημενες οφθαλμικες ενωσεις κετοτιφενης
TW200738143A (en) Use of arylanilides for seed treatment
EA200800785A1 (ru) 4-арил-1,4-дигидро-3(2н)-изохинолиноны и 4-арил-1,2,3,4-тетрагидроизохинолины в качестве ингибиторов igf-1r и в качестве фармакологического средства в тест-системах, фармацевтическая композиция и изделие на их основе и способ лечения заболеваний, опосредованных igf-1 рецептором
DE502004012196D1 (de) Verwendung von isorhamnetin zur behandlung von depressiven verstimmungen und erkrankungen